NCT00871000 - Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. | Biotech Hunter

Enrollment

303

Participants

Timeline

Start Date

April 1, 2009

Primary Completion Date

November 18, 2009

Study Completion Date

November 18, 2009

Conditions

Acellular PertussisTetanusDiphtheriaPoliomyelitis

Interventions

BIOLOGICAL

Boostrix Polio™ 711866

Single dose, intramuscular administration.

BIOLOGICAL

Priorix Tetra TM 208136

Single dose, subcutaneously.

BIOLOGICAL

Tetravac TM

Single dose, intramuscular administration.

Trial Locations (8)

GSK Investigational Site, Genoa

GSK Investigational Site, Milan

GSK Investigational Site, Novara

GSK Investigational Site, Catania

GSK Investigational Site, Modica (RG)

GSK Investigational Site, Ragusa

GSK Investigational Site, Cagliari

GSK Investigational Site, Vittoria (RG)